OBJECTIVE: To study the human risk and benefit of oral pyridoxine (vitamin B6) treatment during pregnancy. DESIGN AND SETTING: The analysis of cases with 25 congenital abnormality (CA) groups and their all-matched controls without CAs in the population-based dataset of the large Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. STUDY PARTICIPANTS: 22,843 cases of pregnant women who had newborns or fetuses with CAs and 38,151 pregnant women who had newborn infants without any CAs (control group). MAIN OUTCOME MEASURES: Prevalence of pyridoxine use in early pregnancy among mothers of cases with different CAs and control mothers with infants without any CA. RESULTS: 2013 (8.8%) case mothers and 4086 (10.7%) control mothers were treated with pyridoxine (adjusted prevalence odds ratio [POR] 0.8; 95% confidence interval [CI] 0.7, 0.9). The analysis of cases with different defects and their all-matched controls did not indicate any obvious teratogenic potential of pyridoxine use during the second and third months of gestation, i.e. in the critical period for the development of most major CAs. However, some protective effect was found for cardiovascular malformations (adjusted POR 0.8; 95% CI 0.7, 0.9). CONCLUSION: Treatment with pyridoxine during pregnancy does not indicate a teratogenic risk to the fetus, but may provide some protective effect for cardiovascular malformations. Copyright 2004 Adis Data Information BV
OBJECTIVE: To study the human risk and benefit of oral pyridoxine (vitamin B6) treatment during pregnancy. DESIGN AND SETTING: The analysis of cases with 25 congenital abnormality (CA) groups and their all-matched controls without CAs in the population-based dataset of the large Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. STUDY PARTICIPANTS: 22,843 cases of pregnant women who had newborns or fetuses with CAs and 38,151 pregnant women who had newborn infants without any CAs (control group). MAIN OUTCOME MEASURES: Prevalence of pyridoxine use in early pregnancy among mothers of cases with different CAs and control mothers with infants without any CA. RESULTS: 2013 (8.8%) case mothers and 4086 (10.7%) control mothers were treated with pyridoxine (adjusted prevalence odds ratio [POR] 0.8; 95% confidence interval [CI] 0.7, 0.9). The analysis of cases with different defects and their all-matched controls did not indicate any obvious teratogenic potential of pyridoxine use during the second and third months of gestation, i.e. in the critical period for the development of most major CAs. However, some protective effect was found for cardiovascular malformations (adjusted POR 0.8; 95% CI 0.7, 0.9). CONCLUSION: Treatment with pyridoxine during pregnancy does not indicate a teratogenic risk to the fetus, but may provide some protective effect for cardiovascular malformations. Copyright 2004 Adis Data Information BV
Authors: Weizhi Zhao; Bridget S Mosley; Mario A Cleves; Stepan Melnyk; S Jill James; Charlotte A Hobbs Journal: Birth Defects Res A Clin Mol Teratol Date: 2006-04